tiprankstipranks
Advertisement
Advertisement

RGEN Stock Latest News

Repligen–BioLife Deal: Market, Integration and Regulatory Risks Threaten Growth Outlook and Shareholder Returns
Company AnnouncementsRepligen–BioLife Deal: Market, Integration and Regulatory Risks Threaten Growth Outlook and Shareholder Returns
2d ago
RGEN
Repligen’s Operational Momentum Offset by Full Valuation; Kyle Mikson CFA Reiterates Hold with Unchanged $145 Price Target
PremiumRatings
Repligen’s Operational Momentum Offset by Full Valuation; Kyle Mikson CFA Reiterates Hold with Unchanged $145 Price Target
4d ago
RGEN
Repligen Stock (RGEN) Rises After Investors Wowed By ‘Market Leading’ Q2 Figures
PremiumMarket News
Repligen Stock (RGEN) Rises After Investors Wowed By ‘Market Leading’ Q2 Figures
4d ago
RGEN
Repligen price target raised to $175 from $165 at JPMorgan
PremiumThe Fly
Repligen price target raised to $175 from $165 at JPMorgan
4d ago
RGEN
Repligen rises 15.4%
PremiumThe Fly
Repligen rises 15.4%
5d ago
RGEN
Repligen Earns Buy Rating on Strong Q2 Beat, Raised Guidance, and Broad-Based Demand Strength
PremiumRatingsRepligen Earns Buy Rating on Strong Q2 Beat, Raised Guidance, and Broad-Based Demand Strength
5d ago
RGEN
Repligen rises 16.2%
Premium
The Fly
Repligen rises 16.2%
5d ago
RGEN
Repligen reports Q2 adjusted EPS 54c, consensus 45c
Premium
The Fly
Repligen reports Q2 adjusted EPS 54c, consensus 45c
5d ago
RGEN
Repligen raises FY26 EPS view to $2.03-$2.09 from $1.97-$2.05, consensus $2.00
PremiumThe Fly
Repligen raises FY26 EPS view to $2.03-$2.09 from $1.97-$2.05, consensus $2.00
5d ago
RGEN
RGEN Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
RGEN Upcoming Earnings Report: What to Expect?
7d ago
RGEN
Midday Fly By: AT&T reports Q2 beat, AMD invests $5B in Anthropic
PremiumThe Fly
Midday Fly By: AT&T reports Q2 beat, AMD invests $5B in Anthropic
11d ago
T
PM
BioLife Solutions downgraded to Hold from Buy at Lake Street
PremiumThe Fly
BioLife Solutions downgraded to Hold from Buy at Lake Street
11d ago
BLFS
RGEN
Repligen to Acquire BioLife, Expanding Cell Therapy Reach
PremiumCompany AnnouncementsRepligen to Acquire BioLife, Expanding Cell Therapy Reach
11d ago
8K
RGEN
Repligen Earns Buy Rating on BioLife Acquisition Synergies and Strong Organic Growth
Premium
Ratings
Repligen Earns Buy Rating on BioLife Acquisition Synergies and Strong Organic Growth
11d ago
RGEN
Repligen to acquire BioLife Solutions for $31 per share, or $1.5B
Premium
The Fly
Repligen to acquire BioLife Solutions for $31 per share, or $1.5B
11d ago
BLFS
RGEN
Repligen to acquire BioLife Solutions for $31 per share, or $1.5B
PremiumThe Fly
Repligen to acquire BioLife Solutions for $31 per share, or $1.5B
11d ago
BLFS
RGEN
SpaceX initiated, Cloudflare upgraded: Wall Street’s top analyst calls
PremiumThe Fly
SpaceX initiated, Cloudflare upgraded: Wall Street’s top analyst calls
26d ago
KC
AAL
Repligen upgraded to Buy from Hold at Benchmark
PremiumThe Fly
Repligen upgraded to Buy from Hold at Benchmark
26d ago
RGEN
Repligen price target raised to $160 from $150 at Evercore ISI
PremiumThe Fly
Repligen price target raised to $160 from $150 at Evercore ISI
27d ago
RGEN
Biolife attracts takeover interest from Repligen, Bloomberg says
PremiumThe FlyBiolife attracts takeover interest from Repligen, Bloomberg says
1M ago
BLFS
RGEN
Repligen price target lowered to $150 from $170 at HSBC
Premium
The Fly
Repligen price target lowered to $150 from $170 at HSBC
2M ago
RGEN
Repligen assumed with an Outperform at Wolfe Research
Premium
The Fly
Repligen assumed with an Outperform at Wolfe Research
2M ago
RGEN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >